Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
April 03, 2023 07:33 ET
|
Novartis Pharma AG
Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) is now approved in the EU for use in all indications of reference medicine Humira®*HCF formulation adalimumab offers...
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
March 21, 2023 10:48 ET
|
Novartis Pharma AG
Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will offer...
Novartis will das Sandoz Geschäft durch eine hundertprozentige Ausgliederung als eigenständiges Unternehmen abspalten
August 25, 2022 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Die strategische Überprüfung von Sandoz hat ergeben, dass eine Abspaltung von Sandoz durch eine hundertprozentige Ausgliederung im besten Interesse der...
Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
August 25, 2022 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Sandoz strategic review concludes that a separation of Sandoz by way of a 100% spin-off is in the best interest of shareholders, creating the #1...
Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
July 21, 2022 01:15 ET
|
Novartis Pharma AG
Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand access to medicine for patients with chronic...
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
June 22, 2022 20:01 ET
|
Novartis Pharma AG
Novartis endorses the Kigali Declaration on neglected tropical diseases, pledging USD 250 million to advance R&D of new treatments against NTDs and malaria over five yearsCommitment includes USD...
Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030
May 31, 2022 01:15 ET
|
Novartis Pharma AG
Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders Action Plan will provide roadmap...
Novartis accelerates efforts toward ESG targets to increase access to medicines, improve health equity and achieve net-zero carbon emissions
September 30, 2021 01:15 ET
|
Novartis Pharma AG
Reached nearly 29 million patients to date in 2021 through our flagship programs and strategic innovative brandsAnnounced a planned 10-year commitment with historically black colleges and universities...
ModivCare Partners with the Michigan Department of Community Health and FEMA to Provide Critical Vaccine-Related Transportation to Ford Field
May 20, 2021 09:00 ET
|
ModivCare
Detroit, MI, May 20, 2021 (GLOBE NEWSWIRE) -- ModivCare Inc. (“ModivCare” or the “Company”) (Nasdaq: MODV), a technology enabled healthcare services company that provides a suite of integrated...
Maine Food Delivery Effort Turns to ModivCare for Support In Delivering Food to Students and Families in Aroostook County
March 08, 2021 09:00 ET
|
LogistiCare
Aroostook County, ME, March 08, 2021 (GLOBE NEWSWIRE) -- Melanie Lagasse, Food Service Director at Valley Unified Education Service Center (MSAD 27, MSAD 33 and Madawaska School Department)...